Despite tremendous research effort in the field, our current understanding of the molecular mechanisms underlying neuropathic pain is still incomplete. In the present study, our objective was to elucidate the involvement of the Wnt/␤-catenin signaling pathway in the development of neuropathic pain. We showed that Wnt/␤-catenin signaling is activated in the spinal cord dorsal horn after partial sciatic nerve ligation (PSL). Expression of Wnt3a, a prototypic Wnt ligand that activates the Wnt/␤-catenin pathway, was also upregulated in the dorsal horn. We then tested the effect of intrathecal administration of XAV939, a Wnt/␤-catenin signaling inhibitor, and found that this treatment effectively attenuated the induction of neuropathic pain. Conversely, intrathecal administration of Wnt3a to the lumbar spinal cord of naïve animals triggered the development of allodynia. These results suggest a critical involvement of the Wnt/␤-catenin pathway in the development of neuropathic pain. Moreover, we also found that PSL-induced microglial activation was significantly suppressed by intrathecal administration of XAV939 treatment. Because it was revealed that Wnt3a treatment triggered brain-derived neurotrophic factor (BDNF) release from microglial cells in vitro, it is possible that Wnt3a upregulation in the dorsal horn leads to the activation of microglial cells, then triggers BDNF secretion that is responsible for the establishment of neuropathic pain. Further studies will be needed for the comprehensive understanding of the roles of Wnt/␤-catenin signaling in the development of neuropathic pain.
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Introduction
Clinical management of neuropathic pain is currently aimed at achieving relief from symptoms of this condition; unfortunately, in many cases such efforts fall short of this goal. Therefore, efforts to develop disease-modifying therapeutics that effectively treat neuropathic pain are of great importance. Previous studies have revealed that numerous processes are involved in the development of neuropathic pain, including structural changes in neural circuits in the spinal cord dorsal horn (Woolf et al., 1992; Navarro et al., 2007) and abnormal excitability due to alterations of neurotransmitter release (Basbaum et al., 2009) . Moreover, recent studies provide increasing evidence for the role of inflammatory processes, via the actions of immune cells and glial cells, in the development of neuropathic pain (Scholz and Woolf, 2007; Ellis and Bennett, 2013) . Nevertheless, our knowledge of the molecular mechanisms underlying these processes is very limited.
Wnt family proteins play important roles in many aspects of central nervous system (CNS) development: neural induction, cell proliferation, neuronal migration, axon guidance, dendritic arborization, and synaptogenesis (Ciani and Salinas, 2005; Salinas, 2012; Park and Shen, 2012) . At least three Wnt signaling pathways have been demonstrated; these include the canonical Wnt/␤-catenin pathway, planar cell polarity pathway, and Wnt/Ca 2+ pathway. Among them, the Wnt/␤-catenin pathway is the best understood, and previous studies have suggested its possible contributions to the pathogenesis of several CNS disorders, including cerebral ischemia (Zhang et al., 2008; Mastroiacovo et al., 2009) , psychiatric disorders (Okerlund and Cheyette, 2011), Parkinson's disease (L'Episcopo et al., 2011), Alzheimer's disease (Shruster et al., 2011; Halleskog et al., 2011), and epilepsy (Busceti et al., 2007) . Moreover, recent studies suggest the involvement of Wnt signaling in generating inflammatory responses in the CNS through glial cell modifications (Marchetti and Pluchino, 2013) . This suggests the possible involvement of Wnt signaling in various aspects of the development of neuropathic pain.
In the Wnt/␤-catenin pathway, Wnt ligands bind to Frizzled (Fzd) and LRP5/6. Subsequent binding of Fzd to the scaffold protein Disheveled (Dvl) leads to the inhibition of the destruction complex, a group of proteins which include Dvl, axin, glycogen synthase kinase-3␤ (GSK-3␤), casein kinase 1, and adenomatous polyposis coli (APC) protein. In the absence of Wnt, the destruction complex
